Ridgetech Inc（RDGT）股票分析

AI 分析 of Ridgetech Inc (RDGT)

買進

Ridgetech, Inc. appears to be a good buy right now due to its recent price increase of 36.78% yesterday and a 5-day change of 27.05%. The stock is currently trading at $1.02, which is significantly below its 52-week high of $760.50, indicating potential for recovery. The RSI is at 74.734, suggesting that the stock is overbought, but the momentum could continue given the recent bullish sentiment following the reverse stock split. However, the main risk is its extreme volatility, as evidenced by a year-to-date change of -99.74%, which highlights the potential for significant price fluctuations.

估值指標

Ridgetech Inc（RDGT）目前預期本益比為 1.11，5 年平均預期本益比為 9.47。

預期本益比

合理

5 年均值 P/E

9.47

目前P/E

1.11

高估

33.88

低估

-14.93

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

嚴重低估

5 年均值 P/S

0.00

目前P/S

0.00

高估

0.00

低估

0.00

Alphio AI 對 RDGT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%RDGT

$1.29

情境價格

基

基準

基準 · 50%RDGT

$1.24

情境價格

悲

悲觀

悲觀 · 25%RDGT

$1.00

情境價格

RDGT 常見問題 —— 由 Alphio AI 解答

Ridgetech Inc, formerly China Jo-Jo Drugstores Inc, is a retailer and distributor of pharmaceutical and other healthcare products. The Company operates in four business segments. The Retail Drugstores segment sells prescription and over the counter (OTC) medicines, traditional Chinese medicine (TCM), dietary supplements, medical devices, and sundry items to retail customers. The Online Pharmacy segment sells OTC drugs, dietary supplements, medical devices and sundry items through its own and third-party platforms. The Wholesale Business segment includes supplying the Company's own retail drugstores and selling them to other drug vendors and hospitals. The Farming and Selling Herbs segment cultivates selected herbs for sales to other drug vendors. It operates in the Consumer Cyclicals sector.

Ridgetech, Inc. appears to be a good buy right now due to its recent price increase of 36.78% yesterday and a 5-day change of 27.05%. The stock is currently trading at $1.02, which is significantly below its 52-week high of $760.50, indicating potential for recovery. The RSI is at 74.734, suggesting that the stock is overbought, but the momentum could continue given the recent bullish sentiment following the reverse stock split. However, the main risk is its extreme volatility, as evidenced by a year-to-date change of -99.74%, which highlights the potential for significant price fluctuations.